Akeso, Inc. (9926.HK) is a biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of new innovative antibody drugs that are affordable to patients worldwide.
Since our establishment, the Company has established an comprehensive in-house drug development platform (ACE Platform), encompassing fully integrated drug discovery and development functions, including target validation, antibody drug discovery and development, process development, and GMP-compliant commercial scale manufacturing. The Company has also successfully established a bi-specific antibody drug development technology platform (Tetrabody Technology Platform). The Company currently has a pipeline of over 20 innovative investigative drugs for the treatment of major diseases like cancer and autoimmune diseases, 12(including 3 out licensed) of which have entered clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The Company’s vision is to become a global leading biopharmaceutical company through research and development of break-through new drugs that are first-in-class and best-in-class therapies.
In oncology therapeutic area, the products in advanced development include an anti-PD-1/CTLA-4 bi-specific antibody (德赢), an anti-PD-1 antibody (penpulimab (官网)) , and AK112, a potential first-in-class PD-1/VEGF bi-specific antibody. In immunology therapeutic area, the Company has built one of the richest pipeline targeting autoimmune diseases among China-based biotech companies. Our product candidates in this area include anti-IL12/IL23 monospecific antibody (AK101), an anti-IL17 monospecific antibody (AK111), one drug candidate with IND approved in Australia (AK120, an IL-4R antibody), and one more in IND-enabling stage (AK114, an IL-1 beta antibody.